Esperion Launches New Scientific Website
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street lower on AI spending jitters; oil prices rebound
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Morgan Stanley Opens Catalyst Driven Idea on Esperion Therapeutics (ESPR)
February 27, 2023 4:21 PM ESTMorgan Stanley analyst Jeffrey Hung reiterated an Equalweight rating and $9.00 price target on Esperion Therapeutics (NASDAQ: ESPR)
The analyst comments "What is the catalyst? Data from Esperion's CLEAR outcomes study for LDLlowering drug Nexletol (bempedoic acid) in 14,000+ statin intolerant patients at high risk for cardiovascular disease will be presented in a... More



